KPV

Derived from alpha-MSH; binds melanocortin receptors MC1R/MC3R to suppress NF-κB and inflammatory cytokines

KPV (Lys-Pro-Val) is a synthetic C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH) that retains the anti-inflammatory activity of the parent peptide and is of research interest for mucosal inflammatory conditions due to its capacity to be transported across intestinal epithelium via the PepT1 oligopeptide transporter. PepT1, which is upregulated in inflamed intestinal mucosa, internalizes KPV into epithelial cells where it inhibits NF-κB activation and reduces pro-inflammatory cytokine production, providing targeted anti-inflammatory activity at the mucosal level without requiring systemic delivery. Gastroenterology research has demonstrated that PepT1-mediated KPV uptake reduces intestinal inflammation in preclinical colitis models, and subsequent work has characterized oral delivery of KPV via hyaluronic acid-functionalized nanoparticles for improved mucosal targeting in experimental inflammatory bowel disease. KPV is a research compound with no regulatory approval in any jurisdiction; available evidence is limited to in vitro and preclinical animal models, and no human clinical trials have evaluated KPV for any mucosal inflammatory indication. KPV is studied in preclinical research primarily for its anti-inflammatory effects at the mucosal level, intestinal healing responses, and wound repair mechanisms — areas of interest in inflammatory bowel disease and dermatological research contexts. Oral delivery of KPV via PepT1-mediated transport is the primary research interest in IBD and mucosal inflammation contexts; oral capsule formulations — including hyaluronic acid nanoparticle encapsulations — have been studied preclinically to improve mucosal targeting and bioavailability in inflamed intestinal tissue. KPV is also studied in topical applications for wound healing and dermatological inflammation, and subcutaneous injection has been explored for systemic delivery. Preclinical research has investigated KPV in colorectal cancer-associated inflammatory models in addition to colitis contexts, representing a broader research interest in the peptide's anti-inflammatory properties across gastrointestinal tissue. KPV and cancer research: KPV's anti-inflammatory mechanism — specifically its suppression of NF-κB signaling and downstream reduction of pro-inflammatory cytokines including IL-6, TNF-α, and IL-1β — has drawn preclinical research interest in gastrointestinal cancer contexts. Chronic intestinal inflammation is a recognized risk factor for colorectal cancer development, and NF-κB pathway hyperactivation is implicated in both IBD progression and colorectal carcinogenesis. Preclinical studies have evaluated KPV in colitis-associated colorectal cancer models, where reduction of mucosal inflammation via PepT1-mediated KPV delivery was associated with attenuated inflammatory signaling in tumor-adjacent tissue. This research is strictly preclinical — no human data exists evaluating KPV in any oncology context — and KPV is not being studied as a cancer treatment. The interest is in its ability to modulate the inflammatory microenvironment that contributes to cancer-associated tissue damage in gastrointestinal research models.